A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of SSS67 in Healthy Adult Participants Via Single Intravenous Infusion
Latest Information Update: 30 Mar 2026
At a glance
- Drugs SSS 67 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Shenyang Sunshine Pharmaceutical
Most Recent Events
- 30 Mar 2026 New trial record